Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 4/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5950461 | 0.82 | ESR1 (0.46) | HRH3ESR1ESR2CHRM3CYP1A2 | |
| SCHEMBL6575930 | 0.75 | ESR1 (0.52) | ESR1ESR2AR | |
| SCHEMBL28644802 | 0.75 | ESR1 (0.31) | ESR1ESR2 | |
| SCHEMBL4307361 | 0.75 | CYP2C19 (0.56) | ESR1ESR2CHRM3CYP1A2CYP2C9 | |
| SCHEMBL16241468 | 0.74 | CHRM3 (0.33) | CHRM3CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1976050 | 0.73 | TSHR (0.46) | HRH3ESR1ESR2CYP2C9CYP2C19 | |
| SCHEMBL22825393 | 0.73 | HRH3 (0.40) | HRH3ESR1ESR2CHRM3CYP1A2 | |
| SCHEMBL6891134 | 0.73 | ESR1 (0.41) | ESR1ESR2CYP2C19 | |
| SCHEMBL1943661 | 0.73 | ALDH1A1 (0.31) | ESR1ESR2 | |
| SCHEMBL578291 | 0.73 | NPC1 (0.44) | HRH3CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102686587-B | Azaindole glucokinase activators | HOFFMANN LA ROCHE | 2015-05-27 | — | — | CN | claimed |
| EP-2513103-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | claimed |
| US-8222416-B2 | Azaindole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-07-17 | — | — | US | claimed |
| WO-2011073117-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | claimed |
| US-20110144105-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2011-06-16 | — | — | US | claimed |
| EP-1419143-B1 | 24-SULFUR-SUBSTITUTED ANALOGS OF 1ALPHA,25-DIHYDROXY VITAMIN D3 | UNIV JOHNS HOPKINS (US) | 2009-04-15 | — | — | EP | claimed |
| US-7166585-B2 | 24-Sulfur-substituted analogs of 1α,25-dihydroxy vitamin D3 | CYTOCHROMA INC. (CA) | 2007-01-23 | — | — | US | claimed |
| US-20040132695-A1 | 24-Sulfur-substituted analogs of 1 alpha, 25-dihydroxy vitamin D3 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-07-08 | — | — | US | claimed |
| EP-1419143-A1 | 24-SULFUR-SUBSTITUTED ANALOGS OF 1ALPHA,25-DIHYDROXY VITAMIN D3 | JOHNS HOPKINS UNIVERSITY (US) | 2004-05-19 | — | — | EP | claimed |
| US-20030149005-A1 | 24-sulfur-substituted analogs of 1alpha, 25-dihydroxy vitamin D3 | Opko IP Holdings II, Inc. (KY) | 2003-08-07 | — | — | US | claimed |
| WO-2003018545-A1 | 24-SULFUR-SUBSTITUTED ANALOGS OF 1Α,25-DIHYDROXY VITAMIN D¿3? | JOHNS HOPKINS UNIVERSITY (US) | 2003-03-06 | — | — | WO | claimed |
| CN-102686587-B | Azaindole glucokinase activators | HOFFMANN LA ROCHE | 2015-05-27 | — | — | CN | disclosed |
| EP-2513103-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| US-8222416-B2 | Azaindole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-07-17 | — | — | US | disclosed |
| WO-2011073117-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-7166585-B2 | 24-Sulfur-substituted analogs of 1α,25-dihydroxy vitamin D3 | CYTOCHROMA INC. (CA) | 2007-01-23 | — | — | US | disclosed |
| US-20040132695-A1 | 24-Sulfur-substituted analogs of 1 alpha, 25-dihydroxy vitamin D3 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-07-08 | — | — | US | disclosed |
| EP-1419143-A1 | 24-SULFUR-SUBSTITUTED ANALOGS OF 1ALPHA,25-DIHYDROXY VITAMIN D3 | JOHNS HOPKINS UNIVERSITY (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20030149005-A1 | 24-sulfur-substituted analogs of 1alpha, 25-dihydroxy vitamin D3 | Opko IP Holdings II, Inc. (KY) | 2003-08-07 | — | — | US | disclosed |
| WO-2003018545-A1 | 24-SULFUR-SUBSTITUTED ANALOGS OF 1Α,25-DIHYDROXY VITAMIN D¿3? | JOHNS HOPKINS UNIVERSITY (US) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144105-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | HRH3 4610/4885ESR1 3749/4885ESR2 2391/4885 |
| US-20030149005-A1 | 24-sulfur-substituted analogs of 1alpha, 25-dihydroxy vitamin D3 | CYP24A1, CYP2R1, CYP27B1 | HRH3 1363/4885ESR1 1322/4885ESR2 722/4885 |
| US-20040132695-A1 | 24-Sulfur-substituted analogs of 1 alpha, 25-dihydroxy vitamin D3 | CYP24A1, CYP2R1, CYP27B1 | HRH3 1627/4885ESR1 1222/4885ESR2 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.